For instance, Irbelsartan effectively inhibits chemotherapy resistance by suppressing the Hippo/YAP1/c‐Jun/stemness/iron metabolism axis.[59] Gracillin suppresses cancer progression by enhancing the interaction between Merlin and LATS, thereby activating the Hippo signaling pathway.[60] However, small molecule drugs with high selectivity targeting MST1/2 are rarely reported. Here, JUN is linked to cancer.